Free tool
FAERS Monitor: Remicade
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103772 or its brand name (Remicade, Infliximab). Reports on generic versions are filed under their own applications.
Reports
217,587
Serious
192,742
89% of reports
Hospitalization
64,715
Death reported
14,068
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective39,857
- off label use39,149
- condition aggravated20,002
- infusion related reaction19,191
- pain18,649
- rheumatoid arthritis18,613
- arthralgia17,843
- fatigue16,776
- rash13,431
- product use issue13,143
- intentional product use issue13,103
- drug intolerance12,543
- nausea12,320
- alopecia11,916
- joint swelling11,686
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3,914 |
| 2005 | 3,404 |
| 2006 | 3,607 |
| 2007 | 4,090 |
| 2008 | 4,335 |
| 2009 | 5,091 |
| 2010 | 6,225 |
| 2011 | 8,099 |
| 2012 | 12,244 |
| 2013 | 9,120 |
| 2014 | 5,999 |
| 2015 | 12,316 |
| 2016 | 9,599 |
| 2017 | 10,037 |
| 2018 | 11,094 |
| 2019 | 13,337 |
| 2020 | 17,812 |
| 2021 | 13,063 |
| 2022 | 18,658 |
| 2023 | 14,184 |
| 2024 | 12,379 |
| 2025 | 12,090 |
| 2026 | 6,872 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,836,572 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 19,191 | 39.0 | 38.3 | 506,167 |
| rheumatoid arthritisSignal | 18,613 | 18.8 | 18.5 | 263,034 |
| intentional product use issueSignal | 13,103 | 16.8 | 16.5 | 166,543 |
| drug intoleranceSignal | 12,543 | 14.3 | 14.0 | 135,343 |
| joint swellingSignal | 11,686 | 10.3 | 10.1 | 88,647 |
| product use issueSignal | 13,143 | 7.2 | 7.1 | 65,760 |
| condition aggravatedSignal | 20,002 | 6.7 | 6.6 | 92,619 |
| alopeciaSignal | 11,916 | 6.2 | 6.1 | 49,046 |
| off label useSignal | 39,149 | 4.5 | 4.4 | 105,382 |
| arthralgiaSignal | 17,843 | 4.3 | 4.2 | 43,943 |
| rashSignal | 13,431 | 3.0 | 3.0 | 18,210 |
| painSignal | 18,649 | 3.0 | 3.0 | 24,755 |
| drug ineffectiveSignal | 39,857 | 3.0 | 3.0 | 54,368 |
| fatigueSignal | 16,776 | 2.1 | 2.1 | 9,909 |
| nausea | 12,320 | 1.5 | 1.5 | 2,189 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.